Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar i disorder

American Journal of Psychiatry

Volumn 175, Issue 1, 2018, Pages 71-79

  Szegedi, Armin ^a   Durgam, Suresh ^a   Mackle, Mary ^a   Yun Yu, Sung ^a   Wu, Xiao ^a   Mathews, Maju ^a   Landbloom, Ronald P ^a  

^a FOREST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASENAPINE; CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; PLACEBO; PROLACTIN; TRIACYLGLYCEROL; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT;

ADULT; AGITATION; AKATHISIA; ANXIETY; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV; DYSGEUSIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HEART ARREST; HUMAN; HYPERSOMNIA; HYPESTHESIA; INSOMNIA; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MANIA; MIXED MANIA AND DEPRESSION; NAUSEA; OPEN STUDY; ORAL HYPOESTHESIA; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; XEROSTOMIA; AFFECT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DRUG EFFECTS; DRUG MONITORING; KAPLAN MEIER METHOD; PATIENT ACUITY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TIME; TREATMENT OUTCOME;

ADULT; AFFECT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PATIENT ACUITY; PSYCHIATRIC STATUS RATING SCALES; TIME; TREATMENT OUTCOME;

EID: 85040318819     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2017.16040419     Document Type: Article

References (34)

1. Malhi GS, Bassett D, Boyce P, et al: Royal Australian and New ZealandCollegeofPsychiatristsclinicalpracticeguidelinesformood disorders. Aust N Z J Psychiatry 2015; 49:1087–1206
2. Grunze H, Vieta E, Goodwin GM, et al: The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biologicaltreatmentofbipolardisorders:update2012onthelong-term treatment of bipolar disorder. World J Biol Psychiatry 2013; 14: 154–219
3. Yatham LN, Kennedy SH, Parikh SV, et al: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013; 15:1–44
4. Perugi G, Quaranta G, Dell’Osso L: The significance of mixed states in depression and mania. Curr Psychiatry Rep 2014; 16:486
5. Keck PE Jr, Calabrese JR, McIntyre RS, et al: Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007; 68: 1480–1491
6. Calabrese JR, Bowden CL, Sachs GS, et al: A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression: Lamictal 602 Study Group. J Clin Psychiatry 1999; 60:79–88
7. Calabrese JR, Shelton MD, Rapport DJ, et al: Bipolar disorders and the effectiveness of novel anticonvulsants. J Clin Psychiatry 2002; 63(suppl 3):5–9
8. Popovic D, Reinares M, Goikolea JM, et al: Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol 2012; 22:339–346
9. Seroquel XR (package insert). Wilmington, Del., AstraZeneca Pharmaceuticals, 2009
10. Zyprexa (package insert). Indianapolis, Ind., Eli Lilly, 2009
11. Saphris (package insert). Saint Louis, Mo., Actavis, 2015
12. Shahid M, Walker GB, Zorn SH, et al: Asenapine: a novel psycho-pharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009; 23:65–73
13. McIntyre RS, Cohen M, Zhao J, et al: A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009; 11:673–686
14. McIntyre RS, Cohen M, Zhao J, et al: Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord 2009; 11:815–826
15. Sheehan DV, Lecrubier Y, Sheehan KH, et al: The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(suppl 20):22–33
16. Young RC, Biggs JT, Ziegler VE, et al: A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133:429–435
17. Spearing MK, Post RM, Leverich GS, et al: Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73:159–171
18. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382–389
19. Suppes T, Vieta E, Liu S, et al: Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009; 166:476–488
20. Carlson BX, Ketter TA, Sun W, et al: Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). Bipolar Disord 2012; 14:41–53
21. Vieta E, Suppes T, Eggens I, et al: Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008; 109:251–263
22. Bowden CL, Vieta E, Ice KS, et al: Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010; 71:130–137
23. Posner K, Brown GK, Stanley B, et al: The Columbia–Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011; 168:1266–1277
24. Kane JM, Mackle M, Snow-Adami L, et al: A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry 2011; 72:349–355
25. Szegedi A, Zhao J, van Willigenburg A, et al: Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. BMC Psychiatry 2011; 11:101
26. Kapur S, Marques TR: Dopamine, striatum, antipsychotics, and questions about weight gain. JAMA Psychiatry 2016; 73:107–108
27. Solomon DA, Keitner GI, Miller IW, et al: Course of illness and maintenance treatments for patients with bipolar disorder. J Clin Psychiatry 1995; 56:5–13
28. Houston JP, Lipkovich IA, Ahl J, et al: Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: post hoc analysis of patients treated with olanzapine or lithium. J Psychiatr Res 2007; 41:616–621
29. Hong J, Reed C, Novick D, et al: The cost of relapse for patients with a manic/mixed episode of bipolar disorder in the EMBLEM study. Pharmacoeconomics 2010; 28:555–566
30. Iasevoli F, Valchera A, Di Giovambattista E, et al: Affective temperaments are associated with specific clusters of symptoms and psychopathology: a cross-sectional study on bipolar disorder inpatients in acute manic, mixed, or depressive relapse. J Affect Disord 2013; 151:540–550
31. Perlis RH, Ostacher MJ, Patel JK, et al: Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006; 163:217–224
32. Tohen M, Frank E, Bowden CL, et al: The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of courseandoutcomeinbipolardisorders.BipolarDisord2009;11:453–473
33. Keck PE Jr, Calabrese JR, McQuade RD, et al: A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67: 626–637
34. Tohen M, Calabrese JR, Sachs GS, et al: Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163:247–256